New Director Appointed at Vor Biopharma Inc. (VOR)
Vor Biopharma Inc.
Subscribe to track VOR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
New Director Appointed at Vor Biopharma Inc. (VOR)
Company: Vor Biopharma Inc. (VOR) Form: 3 | Filed: 2025/12/19 Significance: Low
Insider: Levin Andrew David Title: null | Relationship: Director
Transaction: This is an initial statement of beneficial ownership (Form 3). The insider reported holding zero shares of the company upon becoming a director.
Key Insight: A new director, Andrew David Levin, has joined the board. This filing establishes his reporting requirement under Section 16 and indicates he does not currently own any company stock.
Market Context: Form 3 filings are procedural and indicate a new insider relationship. They do not represent a trade but are monitored for future insider activity.
Comprehensive Analysis
SEC Filing Analysis: Vor Biopharma Inc. (VOR)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Andrew David Levin has been appointed as a director and filed an initial statement of ownership, reporting no holdings in Vor Biopharma Inc.
- Market Impact: Neutral. This is a standard corporate governance filing required for new insiders.
Company Information
| Field | Value |
|---|---|
| Company | Vor Biopharma Inc. |
| Ticker Symbol | VOR |
| CIK | 0001817229 |
| Industry | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Insider Information
| Field | Value |
|---|---|
| Name | Levin Andrew David |
| CIK | 0001867539 |
| Title/Position | null |
| Relationship | Director |
Transaction Details
This Form 3 filing indicates that the new insider, Andrew David Levin, owned no securities of the company as of the date of the event (2025-12-18). Form 3 is an initial statement of beneficial ownership and does not report a transaction.
| Field | Value |
|---|---|
| Form Type | 3 |
| Transaction Date | 2025-12-18 |
| Transaction Code | null |
| Security Type | null |
| Shares Involved | 0 |
| Price Per Share | null |
| Total Value | null |
| Shares Owned After | 0 |
| Ownership Type | null |
Financial Impact Assessment
As this filing reports zero shares owned and no transaction occurred, there is no direct financial impact to assess. The filing is informational, establishing the reporting person's status as an insider.
Impact Evaluation
- Market Cap Context: Vor Biopharma is a small-cap company with a market capitalization of approximately $70 million. The appointment of a new director is a routine governance event.
- Ownership Concentration: The insider currently holds 0% of the company's shares.
- Transaction Significance: The significance is Low as no transaction took place. The filing's purpose is to comply with SEC regulations for new insiders.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: A Form 3 filing reporting zero initial holdings is a procedural requirement and does not provide any new information that would typically influence the stock price.
Volume & Sentiment
- Expected Volume Impact: Negligible. This type of filing rarely impacts trading volume.
- Sentiment Indicator: Neutral. The event is a standard corporate action.
Additional Context
Transaction Notes
- Event: This filing was triggered by Andrew David Levin becoming a director of Vor Biopharma Inc. on December 18, 2025.
- Holdings: The filing explicitly states that the reporting person owns no securities of the issuer.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.